Literature DB >> 31246251

Comparison of CDH1 Penetrance Estimates in Clinically Ascertained Families vs Families Ascertained for Multiple Gastric Cancers.

Maegan E Roberts1, John Michael O Ranola2, Megan L Marshall1, Lisa R Susswein1, Sara Graceffo1, Kelsey Bohnert1,3, Ginger Tsai2, Rachel T Klein4, Kathleen S Hruska1, Brian H Shirts2.   

Abstract

IMPORTANCE: CDH1 pathogenic variants have been estimated to confer a 40% to 70% and 56% to 83% lifetime risk for gastric cancer in men and women, respectively. These are likely to be overestimates owing to ascertainment of families with multiple cases of gastric cancer. To our knowledge, there are no penetrance estimates for CDH1 without this ascertainment bias.
OBJECTIVE: To estimate CDH1 penetrance in a patient cohort not exclusively ascertained based on strict hereditary diffuse gastric cancer (HDGC) criteria. DESIGN, SETTING, AND PARTICIPANTS: Retrospective review of 75 families found to have pathogenic variants in CDH1 through clinical ascertainment and multigene panel testing at a large commercial diagnostic laboratory from August 5, 2013, to June 30, 2018. CDH1 pathogenic variants were identified in 238 individuals from 75 families. Pedigrees from those families included cancer status for 1679 relatives. Penetrance estimates are based on 41 families for which completed pedigrees were available. MAIN OUTCOMES AND MEASURES: Gastric cancer standardized incidence ratio estimates relative to Surveillance, Epidemiology, and End Results (SEER) Program incidence for pathogenic CDH1 variants from families ascertained without regard to HDGC criteria.
RESULTS: Among the 238 individuals with a CDH1 pathogenic variant, mean (SD) age was 49.3 (18.1) years and 63.4% were female. Ethnicity was reported for 67 of 75 (89%) families; of these 67 families, 51 (76%) reported European ancestry, whereas Asian, African, Latino, and 2 or more ancestries were reported for 4 families (6%) each. Standardized incidence ratios for gastric and breast cancer were significantly elevated above SEER incidence. Extrapolated cumulative incidence of gastric cancer at age 80 years was 42% (95% CI, 30%-56%) for men and 33% (95% CI, 21%-43%) for women with pathogenic variants in CDH1, whereas cumulative incidence of female breast cancer was estimated at 55% (95% CI, 39%-68%). International Gastric Cancer Linkage Consortium criteria were met in 25 of the 75 (33%) families; however, dispensing with the requirement of confirmation of HDGC histologic subtype, 43 (57%) would meet criteria. CONCLUSIONS AND RELEVANCE: The cumulative incidence of gastric cancer for individuals with pathogenic variants in CDH1 is significantly lower than previously described. Because prophylactic gastrectomy can have bearing upon both physical and psychological health, further discussion is warranted to assess whether this surgical recommendation is appropriate for all individuals with pathogenic variants in CDH1.

Entities:  

Year:  2019        PMID: 31246251      PMCID: PMC6604087          DOI: 10.1001/jamaoncol.2019.1208

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


  25 in total

1.  CDH1 on Multigene Panel Testing: Look Before You Leap.

Authors:  Bryson W Katona; Dana Farengo Clark; Susan M Domchek
Journal:  J Natl Cancer Inst       Date:  2020-04-01       Impact factor: 13.506

Review 2.  The risk of diffuse-type gastric cancer following diagnosis with gastric precancerous lesions: a systematic review and meta-analysis.

Authors:  John E Wang; Sung Eun Kim; Bong Eun Lee; Sungho Park; Joo Ha Hwang; Robert J Huang
Journal:  Cancer Causes Control       Date:  2021-11-19       Impact factor: 2.506

3.  Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast.

Authors:  Siddhartha Yadav; Chunling Hu; Katherine L Nathanson; Jeffrey N Weitzel; David E Goldgar; Peter Kraft; Rohan D Gnanaolivu; Jie Na; Hongyan Huang; Nicholas J Boddicker; Nicole Larson; Chi Gao; Song Yao; Clarice Weinberg; Celine M Vachon; Amy Trentham-Dietz; Jack A Taylor; Dale R Sandler; Alpa Patel; Julie R Palmer; Janet E Olson; Susan Neuhausen; Elena Martinez; Sara Lindstrom; James V Lacey; Allison W Kurian; Esther M John; Christopher Haiman; Leslie Bernstein; Paul W Auer; Hoda Anton-Culver; Christine B Ambrosone; Rachid Karam; Elizabeth Chao; Amal Yussuf; Tina Pesaran; Jill S Dolinsky; Steven N Hart; Holly LaDuca; Eric C Polley; Susan M Domchek; Fergus J Couch
Journal:  J Clin Oncol       Date:  2021-10-21       Impact factor: 44.544

Review 4.  Hereditary diffuse gastric cancer: updated clinical practice guidelines.

Authors:  Vanessa R Blair; Maybelle McLeod; Fátima Carneiro; Daniel G Coit; Johanna L D'Addario; Jolanda M van Dieren; Kirsty L Harris; Nicoline Hoogerbrugge; Carla Oliveira; Rachel S van der Post; Julie Arnold; Patrick R Benusiglio; Tanya M Bisseling; Alex Boussioutas; Annemieke Cats; Amanda Charlton; Karen E Chelcun Schreiber; Jeremy L Davis; Massimiliano di Pietro; Rebecca C Fitzgerald; James M Ford; Kimberley Gamet; Irene Gullo; Richard H Hardwick; David G Huntsman; Pardeep Kaurah; Sonia S Kupfer; Andrew Latchford; Paul F Mansfield; Takeshi Nakajima; Susan Parry; Jeremy Rossaak; Haruhiko Sugimura; Magali Svrcek; Marc Tischkowitz; Toshikazu Ushijima; Hidetaka Yamada; Han-Kwang Yang; Adrian Claydon; Joana Figueiredo; Karyn Paringatai; Raquel Seruca; Nicola Bougen-Zhukov; Tom Brew; Simone Busija; Patricia Carneiro; Lynn DeGregorio; Helen Fisher; Erin Gardner; Tanis D Godwin; Katharine N Holm; Bostjan Humar; Caroline J Lintott; Elizabeth C Monroe; Mark D Muller; Enrique Norero; Yasmin Nouri; Joana Paredes; João M Sanches; Emily Schulpen; Ana S Ribeiro; Andrew Sporle; James Whitworth; Liying Zhang; Anthony E Reeve; Parry Guilford
Journal:  Lancet Oncol       Date:  2020-08       Impact factor: 41.316

5.  Germline variants and phenotypic spectrum in a Canadian cohort of individuals with diffuse gastric cancer.

Authors:  M Aronson; C Swallow; A Govindarajan; K Semotiuk; Z Cohen; P Kaurah; L Velsher; I Ambus; K Buckley; C Forster-Gibson; W S Meschino; A Blumenthal; R H Kim; S Brar
Journal:  Curr Oncol       Date:  2020-05-01       Impact factor: 3.677

6.  Indications for Total Gastrectomy in CDH1 Mutation Carriers and Outcomes of Risk-Reducing Minimally Invasive and Open Gastrectomies.

Authors:  Elvira L Vos; Erin E Salo-Mullen; Laura H Tang; Mark Schattner; Sam S Yoon; Hans Gerdes; Arnold J Markowitz; Diana Mandelker; Yelena Janjigian; Kenneth Offitt; Daniel G Coit; Zsofia K Stadler; Vivian E Strong
Journal:  JAMA Surg       Date:  2020-11-01       Impact factor: 14.766

7.  Genetic Gastric Cancer Risk Syndromes.

Authors:  Benjamin A Lerner; Xavier Llor
Journal:  Curr Treat Options Gastroenterol       Date:  2020-10-19

8.  Evaluation of confocal laser endomicroscopy for detection of occult gastric carcinoma in CDH1 variant carriers.

Authors:  Samuel A Schueler; Lauren A Gamble; Bryan F Curtin; Samantha M Ruff; Maureen Connolly; Cathleen Hannah; Martha Quezado; Markku Miettinen; Maureen George; Andrew M Blakely; Jonathan M Hernandez; Theo Heller; Christopher Koh; Jeremy L Davis
Journal:  J Gastrointest Oncol       Date:  2021-04

9.  CDH1 Gene Mutation Hereditary Diffuse Gastric Cancer Outcomes: Analysis of a Large Cohort, Systematic Review of Endoscopic Surveillance, and Secondary Cancer Risk Postulation.

Authors:  Matthew G K Benesch; Stuart R Bursey; Andrew C O'Connell; Morag G Ryan; Carrie L Howard; Cecily C Stockley; Alexander Mathieson
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

10.  Genetic and Epigenetic Alterations of CDH1 Regulatory Regions in Hereditary and Sporadic Gastric Cancer.

Authors:  Gianluca Tedaldi; Chiara Molinari; Celina São José; Rita Barbosa-Matos; Ana André; Rita Danesi; Valentina Arcangeli; Mila Ravegnani; Luca Saragoni; Paolo Morgagni; Francesca Rebuzzi; Matteo Canale; Sara Pignatta; Elisa Ferracci; Giovanni Martinelli; Guglielmina Nadia Ranzani; Carla Oliveira; Daniele Calistri; Paola Ulivi
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.